The early (Chronic) form of Chronic Myeloid Leukemia (CML) is most commonly treated with Bcr-Abl tyrosine kinase inhibitors (e.g., imatinib and dasatinib). These drugs effectively counteract the constitutive activation of a BCR-ABL kinase, which derives from a chromosomal transposition of part of the BCR region of chromosome 22 to the ABL gene on chromosome 9. However, the Chronic phase of CML is followed by two progressively more aggressive phases and current therapies are marginally effective in the later Accelerated and Blast Crisis stages of the disease. To prevent and treat refractory forms of CML, there is a need for alternative means targeting molecular processes that fuel progression.
RNA editing is a post-transcriptional process that yields diversified RNA products, which can also have distinct functions. UC inventors have defined a novel target for CML therapeutics. Recent studies have highlighted the importance of ADAR1, which is one of a family of enzymes responsible for A-to-I RNA editing and normal hematopoiesis. Inventors have found that the editing process yields modified cellular RNAs, which have characteristic patterns through the progression of CML from Chronic to Blast Crisis forms of the disease. The crucial role of ADAR1 in both cell differentiation fate and self-renewal of malignant progenitor cells suggests that ADAR1 may provide a potential target for development of therapeutics as well as for diagnosing and monitoring CML patients during therapy.
Methods of use cover inhibiting the expression or functional activity of ADAR1 in order to:
Traditional CML treatment, such as hydroxyurea and imatinib, do not efficiently eradicate leukemia stem cells, which often lead to disease progression and relapse. This approach:
Support for the crucial role for ADAR1 in disease stage-specific RNA editing as well as cell differentiation and self-renewal of hematopoietic stem cells is confirmed by a number of in vivo and in vitro studies:
US rights available for licensure (See WO2013036867)
|United States Of America||Issued Patent||9,611,330||04/04/2017||2012-037|
therapy, therapeutic, cancer, oncology, malignant, stem cell, Chronic Myeloid Leukemia, CML, leukemia, myelodysplastic syndromes, MDS, myeloproliferative neoplasm, MPN, RNA editing, ADAR1, diagnose, diagnosis, prognosis, isoform, signature, biomarker